Investing
Morning Analyst Calls Briefing for Tuesday, November 1, 2022
Published:
This report was sent to Briefing.com subscribers earlier today.
Upgrades:
> BioCryst Pharma (BCRX) upgraded to Outperform from In-line at Evercore ISI; tgt raised to $16
> Danske Bank A/S (DNKEY) upgraded to Buy from Hold at Deutsche Bank
> Denali Therapeutics (DNLI) upgraded to Buy from Neutral at BTIG Research; tgt $38
> KKR (KKR) upgraded to Buy from Neutral at BofA Securities; tgt raised to $60
> Premier (PINC) upgraded to Outperform from Neutral at Robert W. Baird; tgt $41
Downgrades:
> Avista (AVA) downgraded to Neutral from Buy at Mizuho; tgt lowered to $40
> Blueprint Medicines (BPMC) downgraded to Perform from Outperform at Oppenheimer
> Catalent (CTLT) downgraded to Neutral from Buy at BofA Securities; tgt lowered to $60
> Iberdrola SA (IBDRY) downgraded to Equal-Weight from Overweight at Morgan Stanley
> Ocado (OCDGF) downgraded to Underweight from Neutral at JP Morgan
> SeaSpine (SPNE) downgraded to Hold from Buy at Truist; tgt lowered to $6.75
> Twilio (TWLO) downgraded to Underperform from Buy at BofA Securities; tgt lowered to $85
Others:
> Cronos Group (CRON) initiated with a Mkt Perform at Bernstein; tgt $3
> Denali Therapeutics (DNLI) initiated with a Buy at BofA Securities; tgt $40
> OneSpaWorld (OSW) initiated with a Buy at Truist; tgt $12
> Tilray (TLRY) initiated with a Mkt Perform at Bernstein; tgt $3.90
Research calls posted earlier this morning are available here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
